Based on remarkable findings, the U.S. Food and Drug Administration (FDA) granted approval to cemiplimab in February 2021 for the first-line treatment of advanced NSCLC patients with high PD-L1 expression (≥ 50%) [9]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.